Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulla Derhaschnig

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Blood Advances|March 17, 2020
Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient programGeorg Gelbenegger, Christian Schoergenhofer, Ulla Derhaschnig, et al.
Scientific Reports|January 11, 2018
Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testingChristian Schoergenhofer, Michael Schwameis, Christa Firbas, et al.
Microbiology Spectrum|February 2, 2022
Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Detection Tests Using Oral, Anterior Nasal, and Nasopharyngeal Swabs: a Diagnostic Accuracy StudyMichael Wölfl-Duchek, Felix Bergmann, Anselm Jorda, et al.
The Journal of Investigative Dermatology|June 24, 2019
Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous PemphigoidPatricia Colchete Freire, Cristina Herraez Muñoz, Ulla Derhaschnig, et al.
The Lancet. Infectious Diseases|June 3, 2024
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studiesNicole Bézay, Laura Wagner, Vera Kadlecek, et al.
Blood Advances|June 30, 2022
The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand diseaseCihan Ay, Ingrid Pabinger, Katarina D Kovacevic, et al.
The Lancet. Infectious Diseases|April 28, 2025
Immunogenicity and safety of different immunisation schedules of the VLA15 Lyme borreliosis vaccine candidate in adults, adolescents, and children: a randomised, observer-blind, placebo-controlled, phase 2 trialLaura Wagner, Michaela Obersriebnig, Vera Kadlecek, et al.
The Lancet. Infectious Diseases|July 19, 2024
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trialSanthosh Kumar Ghadge, Martina Schneider, Katrin Dubischar, et al.
The Lancet. Infectious Diseases|November 10, 2025
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trialLaura Wagner, Michaela Obersriebnig, Romana Hochreiter, et al.
Blood|December 19, 2018
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trialUlrich Jäger, Shirley D'Sa, Christian Schörgenhofer, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Blood Advances|March 17, 2020
Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient programGeorg Gelbenegger, Christian Schoergenhofer, Ulla Derhaschnig, et al.
Scientific Reports|January 11, 2018
Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testingChristian Schoergenhofer, Michael Schwameis, Christa Firbas, et al.
Microbiology Spectrum|February 2, 2022
Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Detection Tests Using Oral, Anterior Nasal, and Nasopharyngeal Swabs: a Diagnostic Accuracy StudyMichael Wölfl-Duchek, Felix Bergmann, Anselm Jorda, et al.
The Journal of Investigative Dermatology|June 24, 2019
Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous PemphigoidPatricia Colchete Freire, Cristina Herraez Muñoz, Ulla Derhaschnig, et al.
The Lancet. Infectious Diseases|June 3, 2024
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studiesNicole Bézay, Laura Wagner, Vera Kadlecek, et al.
Blood Advances|June 30, 2022
The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand diseaseCihan Ay, Ingrid Pabinger, Katarina D Kovacevic, et al.
The Lancet. Infectious Diseases|April 28, 2025
Immunogenicity and safety of different immunisation schedules of the VLA15 Lyme borreliosis vaccine candidate in adults, adolescents, and children: a randomised, observer-blind, placebo-controlled, phase 2 trialLaura Wagner, Michaela Obersriebnig, Vera Kadlecek, et al.
The Lancet. Infectious Diseases|July 19, 2024
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trialSanthosh Kumar Ghadge, Martina Schneider, Katrin Dubischar, et al.
The Lancet. Infectious Diseases|November 10, 2025
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trialLaura Wagner, Michaela Obersriebnig, Romana Hochreiter, et al.
Blood|December 19, 2018
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trialUlrich Jäger, Shirley D'Sa, Christian Schörgenhofer, et al.
Pageof 6